You are here

Home » Content

Ticari iki hepatit B aşısının immun cevabının karşılaştırılması

Comparative Immune Responses of Two Commercial Hepatitis B Vaccines

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1996

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
One hundred healthy hepatitis B virus (HBV) seronegative persons were enrolled in a single blind randomized study to compare antibody and clinical responses to yeast recombinant S antigen vaccine (YSHBV) (Hepavax-gene, 1 ml: 20 mgr = one dose) and Chinese hamster ovary cells (CHO) recombinant Pre S2 + S vaccine (CS2SHBV) (Genhevac B, 0.5 ml: 20 mgr = one dose). 50participant (group I) received 20 mgr of YSHBV by intramuscular (IM) injection at 0h,1st and 6th months (mo). 50 participants (group II) received 20 mgr of CS2SHBV by IM injection at 0th, 1st and 2nd mo. Serological and biochemical responses were measured at 0th, 1st, 2nd, 3d, 6th and 7th months in both groups. The proportion of vaccines with minor local complaints (mainly local pain, myalgia ) and proportion developing antibody to surface antigen (anti-HBs) were similar for both vaccine groups (p >0.05), but anti-HBs titers were generally higher among recipients of CS2SHBV. Anti-HBs developed in 92% and 96%, in group I and II by 7th month, respectively. These data imply that YSHBV vaccine is as well tolerated and immunogenic as CS2SHBV vaccine. However, further studies are necessary to compare the duration of immunity after vaccination for two vaccines. [Journal of Turgut Özal Medical Center 1996;3(3):169-172]
Bookmark/Search this post with
Abstract (Original Language): 
Ve Çin: Yüz sağlıklı hepatit B virüsü (HBV) seronegatif kişiler antikor ve maya rekombinant S antijeni aşısı (YSHBV) (20 mgr = tek doz Hepavax-gen, 1 ml) klinik yanıtları karşılaştırmak için, tek kör, randomize çalışmaya alındı hamsteri yumurtalık hücreleri (CHO) rekombinant ön S2 + S aşısı (CS2SHBV) (Genhevac B, 0.5 ml: 20 mgr = tek doz). 50participant (grup I) 0h, 1. ve 6. aylarda (mo) intramuskuler (IM) enjeksiyon yoluyla YSHBV 20 mgr aldı. 50 katılımcı (grup II) 1. ve 2. mo, 0th az IM enjeksiyon yoluyla CS2SHBV 20 mgr aldı. Serolojik ve biyokimyasal tepkiler 1., 2., her iki grupta da, 3d 6. ve 7. aylarda, 0th ölçüldü. Küçük yerel şikayetler (ağırlıklı olarak lokal ağrı, miyalji) ve yüzey antijeni orantılı gelişen antikoru (anti-HBs) ile aşı oranı her iki aşı grupları (p> 0.05) için benzer, ama anti-HBs titreleri alıcılar arasında genel olarak daha yüksek idi CS2SHBV. Anti-HBs sırasıyla 7. aya göre grup I ve II'de,% 92 ve% 96 olarak geliştirilmiştir. Bu veriler YSHBV aşısı iyi tolere edilir ve CS2SHBV aşı olarak immünojenik olduğunu ima. Ancak, ileri çalışmalar iki aşı için aşı sonrası bağışıklığın süresini karşılaştırmak için gerekli olan. [Turgut Özal Tıp Merkezi 1996 Dergisi, 3 (3) :169-172]
FULL TEXT (PDF): 
PDF icon arastrmx_5674_3_pp_169-172.pdf
  • 3
169-172
  • Turkish

REFERENCES

References: 

1. Miskovsky E, Gershman K, Clements LM, et al. Comperative safety and immunogenesity of yeast recombinant hepatitis B vaccines containing S and pre S2 + S antigens. Vaccine 1991; 346-50.
2. Andree FE. Summary of safety and efficacy data on a yeast -derived hepatitis vaccine. Am J Med 1989; 81: 14-20.
3. Trepo C, Rangier P, Gassin M, et al. Preliminary results of a randomized comparative immunogenicity study of three recombinantHBV vaccines in healthy medical personel. Confirmation in man of the enhancement of antiHBS response by pre S2. In: Coursaget P, Tong MJ (eds). Progress on hepatitis immunization (WHO) collaque-INSERM, Labbay Eurotext 1990; 194: 239-43.
4. Brown SE, Howard CR, Zucherman AJ, et al. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet 1984; 1: 184-5.
5. Milich DR, Thornton GM, Neurath AR. Enhanced
immunogenicity of the preS region of hepatitis B surface antigen. Science 1985; 228: 1195-9.
6. Gizaris V, Roumeliotou A, Ktenas E, et al. Evoluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre S2 sequences using two different schedules . WHO / National Center for Viral Hepatitis Athens School of Public Health, 1993; 1445-7.
7. Tron F, Degas F, Brechot C. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and pre-S2 sequence. J Infect Dis 1989; 160-2.
8. Hollinger FB, Adam E, Heiberg D. Response to hepatitis B vaccine in a young adult population. In: Szmuness W, Alter HJ, Maynard JE (eds). Viral Hepatitis , The Franklin Institute Press, Philadelphia 1989: 451-66.
9. Center for Disease Control. Recommendations of the Immunization Practices Advisory Committee: Update on hepatitis B prevention . Morbid Mortal Week Rep.1987; 36:
353-66.
10. Hadler SC, Francis DP, Maynard JE. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Eng J Med 1986; 315: 209-14.
11. Park MH, Kim SJ, Gu MB, et al. Studies on the yeast-
Derived hepatitis B vaccine. J Kor Soc Virology 1988; 18:
1-7.
12. Excler JL, Donjou G, Fossati A, et al. Immunogenicity of the hepatitis B vaccine , Genhevac B, given in three injections (0, 1, 6 months) to young school age teenagers.
Med Mal Infect 1995; 25:835-8.

Thank you for copying data from http://www.arastirmax.com